Sanofi Consumer Healthcare India Limited has announced robust financial results for the third quarter and nine months ended September 30, 2026. Revenue for the quarter grew 12% year-on-year to ₹2,631 million, with profit before tax reaching ₹1,027 million, a 22% increase. The nine-month period also saw healthy growth, with revenue up 16% and profit up 24%, driven by domestic and export sales aided by product relaunches.
Sanofi Consumer Healthcare India Reports Strong Q3 Performance
Sanofi Consumer Healthcare India Limited has released its financial results for the quarter and nine months ended September 30, 2026, showcasing significant year-on-year growth. The company’s strategic initiatives and product portfolio strength contributed to a profitable quarter and a strong nine-month performance.
Q3 2026 Financial Highlights
For the third quarter of 2026, Sanofi Consumer Healthcare India Limited reported a revenue of ₹2,631 million, marking a 12% increase compared to the same period in the previous year. Domestic sales saw a substantial rise of 19%. Earnings Per Share (EPS) grew by 22% to INR 5.95, driven by the increased revenue. Profit Before Tax (PBT) for the quarter was ₹1,027 million, up by 22% year-on-year, reflecting improved profitability.
Nine Months Ended September 30, 2026 Performance
The company also reported strong results for the nine months ended September 30, 2026. Revenue from operations reached ₹7,280 million, a growth of 16% compared to the prior year. Domestic sales grew by 15%, significantly aided by successful product relaunches. Export sales also showed strong momentum, increasing by 19%. Profit Before Tax for the nine-month period was up by 24%.
Operational Notes and Business Context
The financial statements were prepared in accordance with Indian Accounting Standards (Ind AS) and reviewed by statutory auditors. The company noted that results might not be fully comparable with the previous year due to product recalls and subsequent relaunches of Combiflam Suspension, Allegra Suspension, and Depura Kids in 2024 and 2025. Sanofi Consumer Healthcare India operates under a single business segment, the ‘Pharmaceutical Business’. The company confirmed it has no subsidiaries, associates, or joint ventures as of September 30, 2026.
Company and Auditor Information
The results were approved by the Board of Directors on October 28, 2026. The review report was issued by Price Waterhouse & Co Chartered Accountants LLP. Sanofi Consumer Healthcare India Limited’s registered office is located in Mumbai, Maharashtra.
Source: BSE
